Howard Hernandez, MD
Child & Adolescent Psychiatry · Boston, MANPI 1508021213
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Johnson & Johnson at 33.8% of the total.
Across 41 payments — averaging $26.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$373
- Sunovion Pharmaceuticals Inc.$263
- Ironshore Pharmaceuticals Inc.$115
- AbbVie$102
- Otsuka America Pharmaceutical, Inc.$83
- Alkermes, Inc.$45
- plus $123 from 4 others
What the payments were for
- Food & beverage$1,09799%
- Education$71%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 11 | $373 |
| Sunovion Pharmaceuticals Inc. | 14 | $263 |
| Ironshore Pharmaceuticals Inc. | 2 | $115 |
| AbbVie | 4 | $102 |
| Otsuka America Pharmaceutical, Inc. | 3 | $83 |
| Alkermes, Inc. | 2 | $45 |
| Corium, LLC | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 1 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Sage Therapeutics, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,104 in reported general payments places this provider in the 80th percentile of 104 child & adolescent psychiatry providers in Massachusetts.
See all child & adolescent psychiatry providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Alprazolam | 23 | $436 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $330 |
| Duloxetine Hcl | 17 | $292 |
| Trazodone Hcl | 12 | $194 |
| Quetiapine Fumarate | 11 | $175 |
| Clonazepam | 30 | $103 |
| Lorazepam | 22 | $98 |
| Buspirone Hcl | 11 | $92 |
| Zaleplon | 11 | $38 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Boston
- David DemasoBoston$41K
- Matthew SiegelBoston$11K
- Janet WozniakBoston$8K
- Joseph Gonzalez HeydrichBoston$7K
- Michael MarcusBoston$4K
- Ranna ParekhBoston$3K
- Joseph BiedermanBoston$3K
- Ireen AhmedBoston$3K
- Annah AbramsBoston$3K
- Yoshio KanekoBoston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.